title: Effect of topically administered platelet-derived growth factor on corneal wound strength.
abstract: Since the cornea is an avascular tissue, the wound healing process is lengthy, with a need for sutures to stabilize the wound for a long time. Platelet-derived growth factor (PDGF) has been shown to accelerate wound healing in rat dermal models. Accelerated healing, if unaccompanied by side effects may reduce suture related complications such as astigmatism and infectious keratitis. This study evaluated the effect of PDGF on wound strength in corneal laceration and penetrating keratoplasty models using New Zealand white albino rabbits. Twenty-two rabbits were used in the corneal laceration model and sixteen rabbits in the penetrating keratoplasty model. The treated rabbits received 385 picomoles/drop of PDGF-BB dissolved in balanced salt solution six times on day 1 and three times a day for the remainder of the study. The control rabbits received balanced salt solution in the same dosing schedule. The pressure required to rupture the wound was measured using a pressure transducer. In the laceration model the PDGF treated group had mean (+/- standard deviation) average pressures on day 7 of 360 +/- 102 mm Hg for wound rupture compared to 210 +/- 102 mm Hg in the control group. (p = 0.005). The average pressures in the penetrating keratoplasty model on day 17 were 707 +/- 201 mm Hg for the controls and 1042 +/- 292 mm Hg for the PDGF treated group (p = 0.026). Histopathological evaluation of eyes not subjected to bursting showed increased fibroblasts at the wound junction with an increase in types III and type IV collagen production.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Ophthalmology, University of Minnesota, Minneapolis.
authors.forename: S
authors.initials: S
authors.lastname: Murali
authors.forename: D R
authors.initials: DR
authors.lastname: Hardten
authors.forename: S
authors.initials: S
authors.lastname: DeMartelaere
authors.forename: O M
authors.initials: OM
authors.lastname: Olevsky
authors.forename: E A
authors.initials: EA
authors.lastname: Mindrup
authors.forename: M L
authors.initials: ML
authors.lastname: Hecht
authors.forename: R
authors.initials: R
authors.lastname: Karlstad
authors.forename: C C
authors.initials: CC
authors.lastname: Chan
authors.forename: E J
authors.initials: EJ
authors.lastname: Holland
mesh_terms: D000287:Administration, Topical; D000818:Animals; D003094:Collagen / Q000378:metabolism; D003315:Cornea / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D065306:Corneal Injuries; D005131:Eye Injuries / Q000188:drug therapy* / Q000503:physiopathology; D005455:Fluorescent Antibody Technique; D015948:Keratoplasty, Penetrating / Q000473:pathology; D009883:Ophthalmic Solutions; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011817:Rabbits; D013529:Surgical Wound Dehiscence / Q000503:physiopathology*; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
chemical_list: D009883:Ophthalmic Solutions; D010982:Platelet-Derived Growth Factor; D003094:Collagen